Management

Print
Homepage  >  MEDTOX Info  >  Investors  >  Management

Richard J. Braun, MBA, JD
Chairman/President/CEO

Richard J. Braun, MBA, JD, was named Chairman of the Board of Directors and President on October 26, 2000. Mr. Braun was named a director and elected as Chief Executive Officer in July 1996. From 1994 until joining the Company, Mr. Braun acted as a private investor and provided management consulting services to the health care and technology industries. From 1992 until 1994, he served as Chief Operating Officer and as a director of EBP, Inc., a NYSE company engaged in managed care. From 1989 through 1991, Mr. Braun served as Executive Vice President, Chief Operating Officer and as a director of Reich and Tang L.P., a NYSE investment advisory and broker dealer firm.

B. Mitchell Owens, MBA
Vice President and COO - Diagnostics Division

B. Mitchell Owens, MBA, was appointed Vice President and Chief Operating Officer of MEDTOX Diagnostics, Inc. on July 17, 2000. Mr. Owens has over 23 years of experience in the diagnostics industry. He joined the Company in 1988 and has served in various positions, including Director of Operations and General Manager. Prior to joining the Company, Mr. Owens was employed by GTE Technical Products Division and Kayser-Roth Corporation in related operations management positions.

Susan E. Puskas, MT (ASCP) SC
Vice President, Quality Assurance, Regulatory Affairs, and COO - Clinical Laboratory Operations

Susan E. Puskas, MT (ASCP) SC, was appointed COO, Clinical Laboratory Operations on June 15, 2010, in addition to her position as Vice President, Quality Assurance and Regulatory Affairs which she has held since May 23, 2002. Ms. Puskas is a board certified Medical Technologist and Specialist in Clinical Chemistry through the American Society of Clinical Pathologists. Ms. Puskas has been with MEDTOX since 1991. With over 35 years of clinical laboratory experience (greater than 30 years as a director/manager/supervisor), she oversees the quality systems and regulatory affairs of the Company as well as the clinical laboratory operations.

James A. Schoonover, MBA
Vice President, Sales & Marketing and CMO

James A. Schoonover, MBA, was named Vice President of Sales and Marketing and Chief Marketing Officer on July 17, 2000. Mr. Schoonover joined the Company in August 1997 and has more than 25 years of experience in sales, public relations and sales management for a variety of service companies. Prior to joining MEDTOX Scientific, Inc., Mr. Schoonover was a Division Vice President for the medical services subsidiary of Olsten Corporation.

Kevin J. Wiersma
Vice President, Chief Administrative Officer, and CFO of MEDTOX Scientific, Inc., and COO - Forensic Laboratory Operations

Kevin J. Wiersma, was appointed Chief Administrative Officer on June 15, 2010. He was named Chief Financial Officer on May 22, 2002 and Chief Operating Officer on July 17, 2000. He was named Vice President on July 20, 1998. Mr. Wiersma joined MEDTOX Laboratories in 1992 and continued with the company following its acquisition by MEDTOX Scientific, Inc. Mr. Wiersma has served in various positions relating to finance and operations management within the Company.

NEWS & INSIGHTS

View a recent article about synthetic drugs in the Minneapolis Star Tribune and learn about the role that MEDTOX played. 

The Department of Transportation’s Final Rule regarding the use of the Federal Drug Testing Custody and Control Form (CCF) has been published in the Federal Register.  Importantly, the Final Rule extends the deadline for use of the old CCF until November 30, 2011, and finalizes procedures for use of the new CCF. View the Federal Register document

View how MyMEDTOX clients can now locate and order drug testing at MEDTOX collection sites online.

View UPS Shipping Detail

Subscribe to the MEDTOX Journal

Workplace Drug Testing Updates

MEDTOX Ethyl Glucuronide confirmations have expanded to include Ethyl Sulfate. More Details

© 2008 MEDTOX Scientific, Inc. All rights reserved.